Sentivera Acquires Haisco's Phase 2 Inflammation Small Molecule for $1.5 Billion
Success Team of Metasera Launches Newco for Immune Diseases
Sentivera Therapeutics, Inc., established by ARCH Venture Partners and Population Health Partners, has acquired Haisco Pharmaceutical Group Co., Ltd.'s (002653.SZ) Phase 2 inflammation asset immediately upon its launch. Both companies applied the venture-building model used in the Metasera deal, where Pfizer Inc. (PFE) acquired the asset for approximately $10 billion. Sentivera was founded in November 2025 in Delaware and secured an initial $83 million in funding to establish its clinical development foundation. The structure aims to combine proven capital with preclinical assets from China to accelerate development and increase global value simultaneously.
$1.5 Billion Deal Combines Cash, Equity, and Performance-Based Payments
Sentivera has secured exclusive rights to develop, manufacture, and commercialize the asset globally, excluding the Chinese region. Haisco receives an upfront payment of $40 million in cash and $35.89 million in equity, representing 17.5% of Sentivera, totaling $75.89 million. Development, approval, and commercialization milestones could reach up to $1.46 billion, with mid-single to low-double-digit royalty rates on net sales after launch. Haisco's chairman, Wang Junmin, also invested $5 million in the funding, aligning the licensor and global developer's interests for the long term.
Clinical Validation Takes Priority Over Code Names for Early-Stage Assets
The licensed asset is an oral small molecule with no disclosed brand name, generic name, or development code, designed to inhibit the onset and progression of Type 2 inflammation. Haisco observed strong anti-inflammatory activity and a favorable safety profile in preclinical studies, and the Chinese NMPA approved the clinical trial protocol in August 2026. The current stage is post-preclinical and preparing for Phase 1 clinical trials, with no human efficacy or tolerability data yet. Therefore, the majority of the deal value being tied to performance-based milestones reflects a rational structure that shares early clinical risk between Sentivera and Haisco.
Dupixent and Oral JAK Inhibitors Set Competitive Benchmarks
The key benchmark in the Type 2 inflammation market is Dupixent/dupilumab, a subcutaneous injection from Sanofi (SNY) and Regeneron Pharmaceuticals (REGN), which blocks IL-4RΞ± to inhibit IL-4 and IL-13 signaling. Dupixent was first approved in the U.S. in 2017 for atopic dermatitis and generated $15.7 billion in sales in 2025, proving the massive commercial potential of a single asset. Oral competitors for atopic dermatitis include Pfizer (PFE)'s Cibinqo/abrocitinib and AbbVie (ABBV)'s Rinvoq/upadacitinib, both targeting JAK1 and approved by the FDA for the same indication in January 2022. For Sentivera's asset to differentiate itself between injectable biologics and oral JAK inhibitors, it must demonstrate target engagement, repeat-dose safety, and oral exposure in Phase 1 clinical trials.
This deal sets a new global pricing benchmark for Chinese immune disease technologies by offering an upfront payment of $75.89 million and up to $1.46 billion in milestones for an asset preparing to enter Phase 1 trials. In the short term, Sentivera's ability to rapidly initiate first-in-human trials and secure safety, pharmacokinetic, and target engagement data will be a key inflection point for its value. Mid- to long-term competitive benchmarks include Dupixent/dupilumab with $15.7 billion in 2025 sales, and FDA-approved oral JAK1 inhibitors Cibinqo/abrocitinib and Rinvoq/upadacitinib. For researchers and development teams, the core challenge remains to broadly control Type 2 inflammation while simultaneously reducing the systemic safety burden of JAK inhibitors and the administration inconvenience of injectables. If the Newco model of ARCH and Population Health is replicated, immune disease transactions combining Asian preclinical assets with Western capital and clinical infrastructure could expand significantly.